We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 06, 2021

VEGFR-TKIs Plus Immune Checkpoint Inhibitors in Metastatic RCC With Favorable Prognosis

Cancer Treatment Reviews


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Treatment Reviews
Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis
Cancer Treat. Rev 2021 Sep 20;100(xx)102295, C Ciccarese, R Iacovelli, C Porta, G Procopio, E Bria, S Astore, MA Cannella, G Tortora

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading